Histopathological Outcomes in Women with High-Risk HPV Infections: A Focus on HPV 31
DOI:
https://doi.org/10.21613/GORM.2025.1606Keywords:
Human Papillomavirus, High-Risk HPV types, , HPV genotyping, cervical dysplasia, cervical intraepithelial neoplasia grade 2 or worseAbstract
OBJECTIVE: To evaluate the histopathological findings of patients with high-risk human papillomavirus (hr-HPV) positivity.
STUDY DESIGN: This retrospective cohort study included 814 women aged 30–65 years who underwent colposcopic evaluation following a positive hr-HPV DNA result detected using the Hybrid Capture 2 test (Qiagen, Hilden, Germany). HPV genotyping and concurrent cervical cytology were performed for all participants.
RESULTS: Among the cohort, 495 women were positive for HPV 16 and/or 18, while 319 had non-16/18 hr-HPV types with negative cervical cytology. Colposcopic biopsy was performed in 515 cases. The prevalence of cervical intraepithelial neoplasia grade 2 or higher (CIN2+) was significantly higher in women with HPV 16/18 and negative cytology (23.3%) compared to those with non-16/18 hr-HPV and negative cytology (3.8%) (p=0.001). In the subgroup with HPV 16/18 positivity, CIN2+ lesions were detected in 42.6% of women with LSIL and 21.2% of those with ASCUS cytology (p=0.043). Among patients with ASCUS cytology, CIN2+ was identified in 40% of those with HPV 31 and only 6.3% of those infected with other non-16/18/31 hr-HPV types (p=0.021). Among patients with non-16/18 HPV DNA types, regardless of cytology, there was no statistically significant difference in terms of CIN2+ lesions between those with HPV type 31 and those with other high-risk types (excluding HPV 16, 18, and 31).
CONCLUSIONS: HPV 16/18 remains the highest-risk group regardless of cytology. Among non-16/18 HPV patients, no significant difference in CIN2+ risk was found between HPV 31 and other types overall. However, HPV 31 poses a higher risk in patients with ASCUS cytology, indicating the need for closer management in this subgroup. Therefore, a more individualized evaluation is recommended for non-16/18 HPV infections.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Serap Ozkan, Sevgi Koc, Yagmur Soykan, Eda Kayali, Derman Basaran

This work is licensed under a Creative Commons Attribution 4.0 International License.
All the articles published in GORM are licensed with "Creative Commons Attribution 4.0 License (CC BY 4.0)". This license entitles all parties to copy, share and redistribute all the articles, data sets, figures and supplementary files published in this journal in data mining, search engines, web sites, blogs and other digital platforms under the condition of providing references.



